In our effort to launch an international phase II trial in ARDS (NCT06308926), Medregen has also successfully submitted an IND for...
Northwestern University has completed recruitment and follow-up of all 10 subjects in the study. The database is expected to be cl...
Medregen is excited to announce that the FDA has approved our IND to initiate a phase IIa, dose-ranging study (NCT06308926) in Acu...
Medregen has initiated its proof of concept, phase II study ‘Safety and Efficacy of MRG-001 in Wound Healing and Scar Appearance...
Medregen is proud to announce that the results of the phase I study (NCT04646603) have been published in Cell Reports Medicine. MR...
Medregen has received IND approval for a phase II, proof of concept to study the Safety and Preliminary Efficacy of MRG-001 in Wou...
A multi-center international trial studying the immunoregulatory and regenerative potential of MRG-001 in severe and critically ill COVID-19 patients has been initiated by MedRegen.
MedRegen has successfully completed the phase I study in healthy volunteers. MRG-001 has demonstrated to be safe across all dosages and effective in the mobilization of stem cells.
MedRegen has teamed up with ICON plc to initiate its first clinical trial in healthy subjects to evaluate the safety, pharmacokinetics and pharmacodynamics of MRG-001 in San Antonio, Texas.
MedRegen is proud to announce that the FDA has approved the IND applications for a combined phase 1/2 clinical trial with MRG-001 for the treatment of COVID-19 disease.